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Background: Hyperuricemia is closely related to renal diseases. Therefore, the aim of this study was to explore the
relationship between the longitudinal changes in serum uric acid and the estimated glomerular filtration rate
(eGFR) in a cohort of elderly hypertensive patients.
Methods: Eighty hundred and thirty-seven re-hospitalized patients with hypertension were included in this
retrospective cohort study. Multiple regression analysis was used to investigate the relationship between changes in
serum uric acid and renal function after 3.5 years follow-up.
Results: The average age at baseline was 69.0+/-10.0 years, and the average follow-up duration was 3.5 years.
Multiple linear regression analysis showed that the baseline uric acid levels had a linearly negative correlation with
baseline eGFR (P < 0.01), after adjustment for age, gender, blood pressure, and body mass index, et al. An increase
of 100 μmol/L baseline uric acid level resulted in a decrease of 5.684 ml/min/1.73 m2 in eGFR [95 % confidence
interval (CI): 7.735-3.633]. Patients with increased uric acid levels had higher risk of renal function decline over the
follow-up period, with an adjusted odds ratio of 1.639 (95 % CI: 1.129-2.378, P = 0.009) , whereas eGFR was
remained unchanged in patients with hyperuricemia at baseline and with normal uric acid level 3.5-year later.
Conclusions: Longitudinal changes in uric acid levels were independently associated with the renal function
decline in elderly patients with hypertension. Uric acid level should be considered in hypertension
management in the elderly.
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Uric acid is an endogenous end product of metabolism
of purine nucleotide. Due to lack of uricase encoding
genes, humans are unable to convert uric acid to soluble
allantoin, leading to higher levels of serum uric acid in
humans than in most of the other mammals that have
uricase encoding genes [1]. Hyperuricemia shows similar
epidemiological trends as hypertension, chronic renal
disease, and type 2 diabetes [2–5], and it is a risk factor* Correspondence: zpl7755@gmail.com
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renal function decline both in healthy subjects [6–8] and
in patients with other related diseases [9]. The risk of
albuminuria significantly increased in patients with
hyperuricemia by 1.27 times in healthy Korean men
(mean age, 52.8 years) with a 5-year follow-up [6]. In a
prospective study among a community-based Chinese
population (mean age, 59.1 years) with the estimated
glomerular filtration rate (eGFR) ≥60 ml/min per
1.73 m2, baseline uric acid levels were independently
associated with an increased risk of renal function
decline, even they still in the ‘normal’ range [7]. Another
prospective study among an elderly Chinese population
(mean age, 74.5 years) in Taiwan had the similar results,istributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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peruricemia predicted a significantly 1.43 times higher
risk for kidney disease among US veterans with gouty
arthritis [9].
Although the relationship between serum uric acid
and renal function decline has attracted increasing atten-
tion, little is known about the importance of uric acid
level with regard to renal damage in elderly patients with
hypertension. Ohta Y et al had reported that an in-
creased uric acid level promoted the renal function
decline in patients with hypertension over a 10-year
observation period [10]. Our earlier study found that
hyperuricemia was an independent risk factor for poor
control of blood pressure during hospitalization in
elderly patients with hypertension [11], and subjects in
our study were much older and had more comorbidity
compared with that in the study of Ohta Y et al. There-
fore, the aim of this study was to determine whether
longitudinal changes in uric acid level were associated
with the renal function in this cohort of elderly hyper-
tensive patients. To the best of our knowledge, this was
the first study focused on whether a decrease in serum
uric acid might slow down the progression of renal
damage in elderly patients with hypertension, inde-
pendent of age, diabetes, and chronic kidney disease.
The result may play an important clinical role in the




In our earlier study, a total of 1648 inpatients with
hypertension were enrolled [11], among whom 865 pa-
tients were re-admitted to Fujian Provincial Hospital
between August 2010 and July 2014. The study was in
compliance with the ethics regulations of the Helsinki
Declaration, and the protocol was approved by the insti-
tutional review board of Fujian Provincial Hospital. All
patients gave oral informed consent to take part in the
original study and for their data to be used. The inclu-
sion criterion was the diagnosis of essential hypertension
on hospital admission. Patients were excluded for any of
the following reasons: hypertension emergencies req-
uiring intravenous infusion of antihypertensive drugs,
severe cardiac insufficiency (grade IV according to the
New York Heart Association), acute coronary syndrome,
acute cerebrovascular accident, unconsciousness due to
any reason, infectious disease, hemodynamic instability
due to any reason, receiving diuretics or allopurinol
within 2 weeks prior to admission, incomplete data on
blood pressure or serum uric acid. Overall, 28 pa-
tients were excluded and 837 patients were included
in the follow-up study with an average follow-up
duration of 3.5 years.Collection of clinical data
The medical history and clinical data were collected at
baseline and readmission, respectively, including medical
history, family history, number and dosage of medica-
tions (antihypertensive agents, antilipemic agents, antidi-
abetic agents, etc.). Blood pressure in the right arm was
measured twice in the supine position, using a manual
sphygmomanometer after at least 10 min of rest, and the
average of the two readings was used for analysis. Any
discomfort was avoided during the blood pressure
measurements. The fasting forearm vein blood (5 ml)
was collected in the morning, and an automatic clinical
chemistry analyzer (Dxc800; Beckman Coulter, CA,
92821) was used to detect the levels of blood glucose,
uric acid, creatinine, triacylglycerol, total cholesterol,
high-density ipoprotein cholesterol (HDL-C), and low-
density lipoprotein-cholesterol (LDL-C).
Diagnostic definition
Hypertension was defined as systolic blood pressure
(SBP) ≥140 mmHg and/or diastolic blood pressure
(DBP) ≥90 mmHg without the use of anti-hypertensive
drugs, or currently taking antihypertensive drugs. Hyper-
uricemia was defined as the level of uric acid >420 μmol/L
in men and >360 μmol/L in women with normal pur-
ine diet. Diabetes was defined as diabetic symptoms
with the level of random blood glucose ≥11.1 mmol/
L, or fasting blood glucose ≥7.0 mmol/L, or blood
glucose ≥11.1 mmol/L at 2 h after loading glucose, or
previously diagnosed diabetes. Patients without diabetic
symptoms required a review on another day. eGFR was
calculated using Cockcroft-Gault formula recom-
mended by the National Kidney Foundation: eGFR in
men = [(140-age) × weight (kg)]/[0.818 × serum creatinine
(μmol/L)], eGFR in women = [(140-age) × weight (kg)]/
[0.818 × serum creatinine (μmol/L) × 0.85]. Antihyperten-
sive therapeutic intensity score was defined as the daily
dose of antihypertensive agents divided by the maximum
FDA approved dose, summed across all medication
classes [12]. Body mass index (BMI) was calculated as
weight (kg) / height squared (m2).
Statistical analysis
All the data were analyzed using the Statistical Package
for the Social Sciences, version 19.0 (SPSS, Inc., Chicago,
IL, USA). All continuous variables were approximately
normal distributed, and were expressed as mean ± stand-
ard deviation. Categorical data were expressed as counts
and percentages with the Chi-square test used to com-
pare differences (e.g. gender, diabetes, administration of
statins, pressure-target rate) between groups. Paired
sample t-test was used to compare differences between
uric acid reduced group and uric acid increased group
both at baseline and 3 years later. Patients were divided
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acid levels, and one-way analysis of variance (ANOVA)
was used to estimate the association of uric acid levels
with other cardiovascular risk factors (e.g. age, hyperten-
sion duration, BMI, SBP, DBP, fasting blood glucose,
triacylglycerol, total cholesterol, HDL-C, LDL-C, and
eGFR) and linear trend test was conducted afterwards. A
multiple linear regression model was constructed to
study the independent association between eGFR and
serum uric acid, after adjustment for other risk factors
such as gender, hypertension duration, BMI, blood pres-
sure, antihypertensive therapeutic intensity score, fasting
blood glucose, and lipid profiles. The value of Durbin-
Watson was approximated to 2 and the standardized
residuals of eGFR were normally distributed. A binary
logistic regression model was used to determine the rela-
tionship of longitudinal changes in uric acid and the renal
function decline, after controlling for other potential con-
founders. The Hosmer and Lemeshow goodness-of-fit test
was used for logistic regression (P > 0.05). A two-sided P
value < 0.05 was considered statistically significant.
Results
The distribution of eGFR and age of all subjects at base-
line were showed in Fig. 1 and Fig. 2, respectively. The
average eGFR and average age was 74.78 ± 28.74 ml/min
per 1.73 m2 and 69.0 ± 10.0 years, respectively. The aver-
age follow-up duration was 3.5 years, and the average of
uric acid level was 349.95 ± 102.06 μmol/L at baseline
and 351.16 ± 114.23 μmol/L at 3.5 years later. There was
no significant difference in uric acid level between base-






Fig. 1 eGFR distribution of the study subjects at baseline. Note: eGFR: estimComparison between patients with hyperuricemia and
patients with normal serum uric acid at baseline
Baseline clinical characteristics of the two groups were
presented in Table 1. Baseline BMI, antihypertensive
therapeutic intensity score, triacylglycerol and LDL-C
were higher in hyperuricemia group (all P < 0.05),
whereas baseline eGFR was lower (P < 0.01). No sig-
nificant differences were observed between the two
groups regarding the age, gender, diabetes history, blood
pressure, fasting blood glucose or total cholesterol.
Association between serum uric acid and eGFR at
baseline
Patients then were divided by quartiles based on the
baseline uric acid level, and the clinical data were shown
in Table 2. The hypertension duration, BMI, antihyper-
tensive therapeutic intensity score, and triacylglycerol
level were increased in accordance with the increase of
uric acid level, while HDL-C level and eGFR were de-
creased. There was a linear decrease in eGFR with the
increases of uric acid level, after adjustment for age,
gender, hypertension duration, BMI, SBP, antihyperten-
sive therapeutic intensity score, triacylglycerol, HDL-C,
and LDL-C. Multiple regression analysis showed that an
increase in the uric acid level by 100 μmol/L led to a
decrease of 5.684 ml/min per 1.73 m2 in eGFR [95 %
confidence interval (CI): 7.735-3.633, P < 0.01] (Table 3).
Association of longitudinal changes in serum uric acid
with eGFR decline 3.5 years later
According to the changes of uric acid throughout the
follow-up period, patients were divided into uric acidn per 1.73m2)







Fig. 2 Age distribution of the study subjects by 5-year group at baseline
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(n = 391). There were 47 patients with the uric acid level
unchanged. As shown in Table 4, The proportion of
patients with diabetes significantly increased (P < 0.01), and
the antihypertensive therapeutic intensity score significantly
decreased (P < 0.05) 3.5 years later in both groups. Besides,
eGFR in uric acid increased group was significantly reducedTable 1 Clinical characteristics between subjects with hyperuricemia
Normal uric acid
Age (years) 68.96 ± 10.01
Men (n, %) 313 (49.87 %)
Hypertension duration (years) 10.8 ± 8.1
Diabetes(n, %) 186 (25.06 %)
chronic kidney disease (n, %) 151 (38.23 %)
Body mass index (kg/m2) 24.43 ± 3.50
Antihypertensive therapeutic intensity score 0.89 ± 0.79
Systolic blood pressure (mmHg) 145.79 ± 18.52
Diastolic blood pressure (mmHg) 79.52 ± 12.57
Fasting blood glucose (mmol/L) 5.84 ± 1.73
Triacylglycerol (mmol/L) 1.58 ± 1.17
Total cholesterol (mmol/L) 4.80 ± 1.92
HDL-C (mmol/L) 1.22 ± 0.41
LDL-C (mmol/L) 2.85 ± 0.94
Uric acid (umol/L) 298.66 ± 67.17
eGFR (ml/min/1.73 m2) 76.91 ± 28.76
Note: 1 mmHg = 0.333 kPa; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-(P < 0.01) 3.5 years later compare with that in uric acid
reduced group, whereas baseline eGFR was similar between
two groups. From the data, we also found that the patients
in uric acid increased group had longer hypertension dur-
ation (P < 0.01). The binary logistic regression showed that
the odds ratio of eGFR reduction in uric acid increased
group was 1.639 (95 % CI: 1.129-2.378, P = 0.009).and with normal uric acid at baseline
(n = 609) Hyperuricemia (n = 256) P
68.95 ± 10.44 0.996
142 (47.41 %) 0.294
9.0 ± 7.3 0.301
77 (25.93 %) 0.892
240 (24.90 %) <0.001
25.43 ± 3.66 <0.001
1.06 ± 0.88 0.010
146.79 ± 20.58 0.484
80.75 ± 13.09 0.198
5.63 ± 1.42 0.066
1.92 ± 1.18 <0.001
5.06 ± 1.30 0.061
1.17 ± 0.35 0.092
3.09 ± 1.16 0.007
466.23 ± 66.61 <0.001
68.95 ± 10.44 0.001
density lipoprotein-cholesterol; eGFR: estimated glomerular filtration rate
Table 2 Characteristics of study population in the stratified quartiles based on the baseline level of serum uric acid
Q1 (n = 233) Q2 (n = 232) Q3 (n = 200) Q4 (n = 200) P
Age (years) 69.5 ± 10.1 69.2 ± 9.9 67.4 ± 9.7* 69.6 ± 10.7 0.102
Men (n, %) 79 (33.0) 107 (46.1)** 127 (63.5)** 142 (71.0)** <0.001
Hypertension duration (years) 8.6 ± 8.2 9.0 ± 8.8 10.1 ± 8.3* 11.4 ± 9.8** <0.001
Diabetes (n, %) 75 (32.2) 69 (29.7) 59 (29.5) 60 (30.0) 0.921
Body mass index (kg/m2) 24.3 ± 3.7 24.2 ± 3.4 25.1 ± 3.3* 25.5 ± 3.8** <0.001
Administration of statins (n, %) 179 (76.8) 183 (78.9) 168 (84.0) 155 (77.5) 0.266
Antihypertensive therapeutic intensity score 0.9 ± 0.8 0.9 ± 0.8 0.9 ± 0.8 1.2 ± 0.9** <0.001
Systolic blood pressure (mmHg) 145.9 ± 18.4 146.2 ± 18.7 144.9 ± 19.7 147.3 ± 20.1 0.673
Diastolic blood pressure (mmHg) 79.1 ± 12.8 79.6 ± 12.6 80.3 ± 12.7 80.7 ± 12.8 0.582
Fasting blood glucose (mmol/L) 6.04 ± 1.98 5.72 ± 1.62 5.74 ± 1.46 5.58 ± 1.38* 0.027
Triacylglycerol (mmol/L) 1.48 ± 1.18 1.62 ± 1.25 1.75 ± 1.16* 1.90 ± 1.07** 0.004
Total cholesterol (mmol/L) 4.95 ± 2.77 4.77 ± 1.21 4.87 ± 1.13 4.92 ± 1.26 0.761
HDL-C (mmol/L) 1.28 ± 0.37 1.23 ± 0.48 1.16 ± 0.33** 1.15 ± 0.35** 0.002
LDL-C (mmol/L) 2.86 ± 0.95 2.88 ± 0.99 2.94 ± 0.96 3.01 ± 1.14 0.491
Uric acid (umol/L) 230.73 ± 43.48 315.12 ± 20.06** 383.37 ± 21.13** 488.50 ± 57.64** <0.001
eGFR (ml/min per 1.73 m2) 78.46 ± 27.98 75.64 ± 27.39 75.02 ± 31.68 68.91 ± 27.70** 0.008
Note: HDL-C high-density lipoprotein-cholesterol, LDL-C low-density lipoprotein-cholesterol, eGFR estimated glomerular filtration rate. Compared with Q1 group
*P < 0.05, **P < 0.01
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further analysis. Four hundred and sixty-five patients had
normal uric acid levels throughout the follow-up period
(292.53 ± 67.57 μmol/L and 290.22 ± 65.82 μmol/L, respect-
ively, defined as N-N group); 116 patients had normal
serum uric acid levels at baseline and had hyperuricemia
later (330.09 ± 59.17 μmol/L and 460.91 ± 82.76 μmol/L,
respectively, defined as N-H group); 114 patients had
hyperuricemia at baseline and normal uric acid level later
(461.25 ± 67.08 μmol/L and 317.11 ± 72.99 μmol/L, respect-
ively, defined as H-N group); 142 patients had hyperurice-
mia throughout the follow-up period (471.91 ± 65.95 μmol/
L and 493.18 ± 100.33 μmol/L, respectively, defined as H-H
group). The eGFR significantly decreased in the N-H group
(P = 0.002), H-H group (P = 0.021), and N-N group
(P = 0.035), while the eGFR remained unchanged in
the H-N group (P = 0.705) (Table 5).Table 3 Effect of level of serum uric acid on eGFR using linear
regression
β (SE) 95 % CI t P
Model 1 -3.368 (0.989) -5.309, -1.427 -3.406 0.014
Model 2 -4.274 (0.984) -6.205, -2.344 -4.345 <0.001
Model 3 -5.684 (1.044) -7.735, -3.633 -5.442 <0.001
Note: eGFR estimated glomerular filtration rate, SE standard error, CI
confidence interval. Model 1 was not adjusted for any factor. Model 2 was
adjusted for age and gender. Model 3 was adjusted for age, gender, body
mass index, systolic blood pressure, antihypertensive therapeutic intensity
score, triacylglycerol, high-density lipoprotein–cholesterol, and low-density
lipoprotein-cholesterol. The adjusted R2 for the multiple linear regression
model was 0.416Discussion
Our study reported for the first time that a decrease in
serum uric acid might slow down the progression of
renal damage in elderly patients with hypertension. In
this study, all subjects were elderly hypertensive patients
(aged about 70 years) with other comorbidity such as
overweight, diabetes and dyslipidemia. Patients with hy-
peruricemia usually had lower eGFR, along with higher
hypertension duration, BMI, antihypertensive thera-
peutic intensity score and triacylglycerol. So we per-
formed the multiple linear regressions to determine the
independent association between uric acid level and
eGFR. The result showed that serum uric acid was
negatively linearly correlated to eGFR independent of
sex, BMI, antihypertensive drugs, and lipid profiles. An
increase of 100 μmol/L baseline uric acid level led to a
decrease of 5.684 ml/min per 1.73 m2 in eGFR.
In the analysis of longitudinal data we found that
patients with increased uric acid level had a signifi-
cantly greater eGFR decline than those patients with
decreased uric acid level, although there was no
significant difference in eGFR between two groups
at baseline. The risk of deterioration in renal func-
tion significantly increased 1.639 times in patients
with increased serum uric acid. On the contrary,
patients with hyperuricemia at baseline but normal
uric acid 3.5 years later (H-N Group) maintained
stable eGFR, indicating that a decrease in serum
uric acid level would help to slow down deterior-
ation of renal function.
Table 4 Characteristics of study population between uric acid reducing group and uric acid increasing group
Uric acid reduced group (n = 399) Uric acid increased group (n = 391)
Baseline At 3 years P Baseline At 3 years P
Age (years) 68.2 ± 10.5 71.7 ± 10.5 <0.001 70.0 ± 9.5 73.7 ± 9.6 <0.001
Men (n, %) 211 (52.9) - - 206 (52.7) - -
Hypertension duration (years) 9.2 ± 8.4 - - 11.4 ± 9.6 - -
Diabetes (n, %) 110 (27.6) 131 (32.8) 0.001 131 (33.5) 153 (39.1) <0.001
Body mass index (kg/m2) 24.59 ± 3.34 24.26 ± 3.61 0.009 25.11 ± 3.87 25.18 ± 4.04 0.558
Administration of statins (n, %) 321 (80.5) 384 (96.2) <0.001 336 (85.9) 353 (90.3) 0.006
Antihypertensive therapeutic intensity score 0.94 ± 0.84 0.81 ± 0.62 0.003 0.95 ± 0.85 0.84 ± 0.63 0.020
Systolic blood pressure (mmHg) 145.43 ± 18.56 141.50 ± 19.36 0.003 131.96 ± 14.88 135.66 ± 17.20 0.001
Diastolic blood pressure (mmHg) 80.32 ± 13.30 77.49 ± 12.14 <0.001 73.83 ± 7.89 72.73 ± 11.46 0.101
Pressure-target rate (n, %) 122 (30.6) 167 (41.9) <0.001 257 (65.7) 139 (35.6) 0.001
Fasting blood glucose (mmol/L) 5.70 ± 1.64 6.11 ± 1.92 <0.001 5.87 ± 1.73 6.05 ± 1.72 0.044
Triacylglycerol (mmol/L) 1.72 ± 1.07 1.48 ± 0.93 <0.001 1.65 ± 1.28 1.63 ± 1.05 0.792
Total cholesterol (mmol/L) 4.94 ± 1.15 4.58 ± 1.28 <0.001 4.81 ± 2.31 4.64 ± 1.22 0.143
HDL-C (mmol/L) 1.22 ± 0.35 1.20 ± 0.42 0.264 1.20 ± 0.44 1.17 ± 0.37 0.186
LDL-C (mmol/L) 3.02 ± 1.08 2.85 ± 1.06 0.010 2.80 ± 0.93 2.89 ± 1.00 0.094
Uric acid (μmol/L) 380.88 ± 100.04 301.19 ± 86.95 <0.001 318.62 ± 94.68 402.20 ± 116.64 <0.001
eGFR (ml/min per 1.73 m2) 73.36 ± 29.61 72.33 ± 27.01 0.539 74.51 ± 26.87 66.24 ± 28.25 <0.001
Note: eGFR estimated glomerular filtration rate, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein-cholesterol. Blood pressure was calculated
as the average of blood pressure on admission and at discharge
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hyperuricemia and renal disease. On one hand, reduc-
tion of uric acid through renal excretion causes hyper-
uricemia. On the other hand, hyperuricemia induces
renal injury via a crystal-independent mechanism invo-
lving renal vasoconstriction mediated by endothelial
dysfunction and activation of renin-angiotensin system
[13]. Recent studies have shown that elevated serum uric
acid is an independent risk factor for renal impairment
irrespective of animal models, healthy population, or
patients with hypertension, diabetes, or chronic renal
diseases [14–17]. Shan Y et al. reported that hyperten-
sion, diabetes and hyperuricaemia were three independ-
ent risk factors for chronic kidney disease in adults over
40 years in Central China [18]. However, prospective
studies on the effect of hypouricemic therapy on renal
function are rare. Malaguarnera et al. conducted a ran-
domized self-cross controlled study in elderly patientsTable 5 Comparison of eGFR between baseline and follow-up categ
Baseline (ml/min per 1.73 m2)
N-N 76.13 ± 27.75
N-H 75.59 ± 28.27
H-N 69.90 ± 30.45
H-H 68.10 ± 27.34
Note: eGFR estimated glomerular filtration rate, N-N group patients with normal uric
at baseline and hyperuricemia 3.5 years later, H-N group patients with hyperuricemi
hyperuricemias throughout the follow-up periodwith hyperuricemia who received urate oxidase or
placebo. The patients treated with urate oxidase had a
significant reduction in serum uric acid and creatinine,
and had an increase in creatinine clearance [19]. Goicoe-
chea et al. found that allopurinol treatment slowed down
the deterioration of renal function in patients with
chronic kidney disease [20]. Another study also showed
the benefits of allopurinol therapy on eGFR and blood
pressure hyperuricemic patients with normal renal func-
tion [21]. A retrospective, observational cohort study
showed that hyperuricemia was not an independent
factor for renal progression in autosomal dominant poly-
cystic kidney disease. However, the correction of hyperuri-
cemia may attenuate renal function decline in patients
with mild renal insufficiency [22].
As mentioned above, subjects in this study were elderly
hypertensive patients with other comorbidity. As shown
in Table 4, the proportion of patients with diabetesorized by longitudinal changes in uric acid level
At 3.5 years (ml/min per 1.73 m2) P
72.64 ± 27.06 0.035
66.32 ± 27.12 0.002
68.78 ± 24.89 0.705
61.94 ± 30.58 0.021
acid throughout the follow-up period, N-H group patients with normal uric acid
a at baseline and normal uric acid 3.5 years later, H-H group patients with
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metabolism with aging. Besides, antihypertensive thera-
peutic intensity score was decreased in all subjects, show-
ing the lack of compliance with hypertension treatment in
the elderly. Both dyslipidemia and hyperuricemia are
common in the elderly, which are the manifestation of
metabolism disorders. Obesity has been demonstrated as
a potentially reversible risk factor for the development of
GFR decline, which may be mediated by the presence of
cardiovascular risk factors including diabetes, hyperten-
sion and dyslipidemia [23]. Our result showed a decrease
in the levels of lipid profiles (including triacylglycerol and
total cholesterol), reflecting the popularity in the use of
statins. Age itself is an independent risk factor for the
decline in renal function. Our study demonstrated that
reduction of uric acid level could preserve renal function
independent of age, diabetes, dyslipidemia and administra-
tion of statins. The result indicates that more attention
should be paid on the serum uric acid for better hyperten-
sion management, especially in reducing the incidence of
chronic kidney disease in the elderly.
As a retrospective cohort study, this study had inevitable
limitations. First, this study could not explain the causal
relationship between hyperuricemia and renal function.
Second, only that information during hospitalization was
collected and 3.5-year was a relatively short follow-up
period. Moreover, diuretics and allopurinol agents are
widely used. Though patients taking these two types of
drugs recently were excluded, the medication history
between two hospitalizations might still have an impact
on uric acid level and renal function. Therefore, the
conclusions of this study should not be extended to all
patients with hypertension. More prospective cohort
studies are required to clarify the protective function of
reduction of uric acid level on renal function in patients
with hypertension.Conclusions
Increased serum uric acid levels contributed to the eGFR
decline in elderly hypertensive patients. Reduction of
serum uric acid may preserve renal function independent
of age, diabetes and dyslipidemia. Hypouricemic therapy
should be considered in hypertension management in
elderly patients with hyperuricemia.
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